Clicky

PepGen Inc.(PEPG)

Description: PepGen, Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGenā€™s Enhanced Deliver Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.


Keywords: Biotechnology Life Sciences Biology Molecular Biology Cell Biology Peptides Serious Diseases Oligonucleotide Nucleic Acids

Home Page: www.pepgen.com

PEPG Technical Analysis

245 Main Street
Cambridge, MA 02142
United States
Phone: 781-797-0979


Officers

Name Title
Dr. James G. McArthur Ph.D. Pres, CEO, Treasurer, Sec. & Director
Ms. Caroline Godfrey Ph.D. Founder & Scientific Advisory Board Member
Mr. Noel Donnelly M.B.A. Chief Financial Officer
Dr. Jaya Goyal Ph.D. Exec. VP of Research & Preclinical Devel.
Dr. Michael Gait Founder & Scientific Advisory Board Member
Dr. Sonia Bracegirdle DPHIL Sr. VP of Strategy & Operations
Ms. Jennifer Cormier Sr. VP of Clinical Operations
Dr. Michelle L. Mellion M.D. Sr. VP & Head of Clinical Devel.
Mr. Niels Svenstrup Ph.D. Sr. VP of Chemistry, Manufacturing & Control
Mr. Kyle Breidenstine VP of Fin. & Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6645
Price-to-Sales TTM: 0
IPO Date: 2022-05-06
Fiscal Year End: December
Full Time Employees: 40
Back to stocks